A Phase 1b Multicenter, Open-label, Single Ascending Dose Study To Evaluate The Safety And Tolerability Of Pf-06939926 In Ambulatory Subjects With Duchenne Muscular Dystrophy
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs PF-06939926 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; First in man
- Sponsors Pfizer
- 11 Dec 2018 Planned End Date changed from 1 Mar 2024 to 1 May 2024.
- 11 Dec 2018 Planned primary completion date changed from 1 Jan 2020 to 1 May 2020.
- 03 Dec 2018 Planned number of patients changed from 20 to 12.